BioSpace58m
GSK-backed Ouro Launches With $115M to ‘Reset’ the Immune System
Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...
Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases
Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated ...
The Independent on MSN46m
Alzheimer’s could be diagnosed 10 years earlier after world’s largest blood proteins study
Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...
BioPharma Dive21m
Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...
ENDPOINTS NEWS58m
With $120M, GSK-al­lied Ouro Med­i­cines throws its hat in­to bur­geon­ing TCE ring
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...
Nicotine Replacement Therapies Market Forecast to Reach $7.52 Billion by 2032: Growing Shift Towards Personalised Nicotine Replacement Therapies
GSK, Pfizer, Johnson & Johnson, Reynolds American, Novartis, Imperial Brands, Cipla Limited, British American Tobacco, Merck ...
ENDPOINTS NEWS49m
Marea re­ports ear­ly Phase 2 da­ta for cho­les­terol-low­er­ing drug it li­censed from No­var­tis
Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.